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ptive, or as some would argue, even overly conservativeInstitute for the Environment, Brunel University, Kingston Lane, Uxbridge UB8
3PH, United Kingdommental data in animals to the general population. This is
routinely conducted by dividing the highest dose not
exhibiting observable toxicity, no observed adverse effect
levels (NOAELs), by a default uncertainty factor of 100.
In the years preceding the implementation of the
European Community Regulation on the Registration,
Evaluation, Authorisation and Restriction of Chemicals
(EC 1907/2006) (REACH) in June 2007, a number of
regarding our understanding of the differences in sensi-
tivity to the toxic effects of chemicals between species
and between individuals alone render a re-analysis both
timely and necessary. This is also now crucial because a
number of myths about the supposed properties of un-
certainty factors do persist and these might have serious
implications for the regulation of mixtures. Principally,
it is often assumed that default uncertainty factors rep-
resent worst-case scenarios and that the multiplication
of their component factors yields sufficiently conserva-* Correspondence: andreas.kortenkamp@brunel.ac.ukAssessing the detrimental health effects of chemicals requires the extrapolation of experimental data in animals to
human populations. This is achieved by applying a default uncertainty factor of 100 to doses not found to be
associated with observable effects in laboratory animals. It is commonly assumed that the toxicokinetic and
toxicodynamic sub-components of this default uncertainty factor represent worst-case scenarios and that the
multiplication of those components yields conservative estimates of safe levels for humans. It is sometimes claimed
that this conservatism also offers adequate protection from mixture effects. By analysing the evolution of
uncertainty factors from a historical perspective, we expose that the default factor and its sub-components are
intended to represent adequate rather than worst-case scenarios. The intention of using assessment factors for
mixture effects was abandoned thirty years ago. It is also often ignored that the conservatism (or otherwise) of
uncertainty factors can only be considered in relation to a defined level of protection. A protection equivalent to
an effect magnitude of 0.001-0.0001% over background incidence is generally considered acceptable. However, it is
impossible to say whether this level of protection is in fact realised with the tolerable doses that are derived by
employing uncertainty factors. Accordingly, it is difficult to assess whether uncertainty factors overestimate or
underestimate the sensitivity differences in human populations. It is also often not appreciated that the outcome of
probabilistic approaches to the multiplication of sub-factors is dependent on the choice of probability distributions.
Therefore, the idea that default uncertainty factors are overly conservative worst-case scenarios which can account
both for the lack of statistical power in animal experiments and protect against potential mixture effects is
ill-founded. We contend that precautionary regulation should provide an incentive to generate better data and
recommend adopting a pragmatic, but scientifically better founded approach to mixture risk assessment.
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As a result, it is also assumed that this degree of conser-
vatism offers adequate protection not only from the
toxic effects of individual substances but also from the
mixture effects of substances. This idea is expressed in
relation to mixtures composed of chemicals that act by
different mechanisms of toxicity, but is often thought to
apply to mixtures generally, regardless of composition
or mode of action. This was recently enunciated by the
European Commission Scientific Committees in their
opinion on the toxicity and assessment of chemical
mixtures [6], and echoed in the recent communication
of the European Commission on the combination ef-
fects of chemicals [7]. Where mixtures are made up of
chemicals thought to have dissimilar modes-of-action,
mixture toxicology theory predicts that the mixture will
be without effect provided that all its constituents can
be shown to have no effect individually. Although the
European Commission Committees now recognise that
the ‘no observed adverse effect’ levels (NOAELs) de-
rived experimentally do not always represent absolute
zero-effect levels due to lack of statistical power, they
conclude that conservative assumptions made when de-
riving safe levels for humans, in other words the appli-
cation of uncertainty factors, render the possibility of
mixture effects unlikely following exposure at the said
safe levels.
These ideas are correct if two unspoken assumptions
are fulfilled: first, that the diversity of chemicals which
make up human exposures act in strictly independent
ways, according to the stochastic principles of the mix-
ture concept of independent action [8]. Under these
conditions, a combination effect is not expected if all
components in the mixture are present at levels equiva-
lent to zero effects. However, cases where experimental
mixtures were shown to follow the principles of inde-
pendent action are few and far between. To date, the ap-
plicability of independent action for multi-component
mixtures has been established for algae [9] and bacteria
[10], but empirical data demonstrating that the concept
is valid in mammalians is missing altogether [11]. There
is however ample evidence that combination effects in
mammals can be adequately described by the alternative
concept of dose addition [12]. However, under dose
addition, combination effects may occur even when all
mixture components are present at levels below dose
thresholds associated with zero effects.
In this review we examine the second assumption im-
plicit in the widely held view of human risk assessors, so
succinctly expressed by the EU Scientific Committees,
namely that current exposures to chemicals generally
pose negligible risks, in line with an “intended level of pro-
tection”. Considering that human populations come into
contact with a multitude of chemicals not appropriatelyassessed toxicologically, this assumption may be some-
what hard to justify in its generality. However, if we re-
strict the debate to chemicals for which acceptable or
tolerable daily intakes (ADI, TDI) are available, the issue
to be examined becomes whether ADI and TDI generally
can be assumed to represent negligible risks, or perhaps
even zero effects. This would be required to fulfil the con-
dition needed to rule out combination effects under inde-
pendent action. If this condition is not met, there is a
strong case for considering mixture effects as part of
chemicals risk assessment.
From the perspective of mixture toxicology, the answer
to this question depends on the conservativeness of the
uncertainty factors that are used to translate NOAELs into
ADIs and TDIs. Are they generally sufficiently protective
to safeguard against the possibility of mixture effects?
We deal with this issue by assessing the perceived con-
servativeness of uncertainty factors through tracing their
origins. From a historical perspective up to the present
day, we first summarise the evolution of the thinking be-
hind uncertainty factors and the unknown quantities
they are purported to represent. In the second part of
this paper, the data available to assess the component
differences in sensitivity that uncertainty factors are sup-
posed to account for is compared against default values
in order to gauge the level of protection afforded. Next,
we consider this level of protection with respect to the
probabilistic approaches applied to the multiplication of
component factors. This will put us in a position to assess
the conservativeness of default uncertainty factors used in
human risk assessment and standard setting. If they can
be shown to be insufficiently protective when dealing with
single chemicals, it will be hard to argue that they also
protect against the effects of combined exposures.
Finally, we return to mixtures risk assessment with the
aim of assessing whether current risk assessment prac-
tices implicitly assume that assessment factors take ac-
count of combination effects.
Historical perspective – is the default a worst-case
scenario?
The introduction of factors interchangeably referred to
as safety, uncertainty, correction, assessment, adjustment
or extrapolation factors cannot be separated from the
need to derive safe levels of additives or contaminants in
food. These factors originate from the emergence of the
ADI, a concept widely credited to European and American
toxicology experts including Truhaut through his involve-
ment in international agencies such as the World Health
Organisation (WHO), Food and Agriculture Organization
(FAO), International Union Against Cancer, Council of
Europe and the European Committee for the Protection
of the Population Against the Hazards of Chronic Toxicity
(EUROTOX) in the early 1950s [13]. The idea of an ADI
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Paracelsus: namely that “All things are poison, and
nothing is without poison; only the dose permits some-
thing not to be poisonous.” which is interpreted to mean
that there is a dose or threshold below which exposure
to a chemical would not result in any detrimental effect
(carcinogenic chemicals are considered an exception to
this rule).
Acceptable daily intake, ‘appreciable risk’ and the desired
level of protection
The ADI was first defined in the WHO Technical Re-
port 240 as “the daily dosage of a chemical, which, dur-
ing an entire lifetime, appears to be without appreciable
risk on the basis of all the facts known at the time” [14].
The term ‘without appreciable risk’ has been mirrored in
European and American definitions of ADIs or Reference
Dose (RfD) respectively [15,16]. A more recent develop-
ment is the explicit inclusion of sensitive or susceptible
subgroups. Although ‘appreciable risk’ has never been
quantitatively defined, guidance from the WHO empha-
sises that “the ADI was an expression of opinion, which
carried no guarantee of "absolute" safety” [17]. The most
recent guidance from the WHO does however mention
that dose–response assessment can be “used to define the
dose associated with a negligible (e.g. 1 in a million) in-
creased response over background” [18]. The report
produced by a Committee on Improving Risk Analysis
Approaches Used by the USEPA also defined a risk-
specific reference dose (for quantal effects) as “the dose
that corresponds to a particular risk specified to be de
minimis (for example, 1 in 100,000) at a defined confi-
dence level (for example, 95%) for the toxicity end point
of concern.” National Research Council, 2008 [16], giving
some tacit indications of both the order of magnitude of
risk (0.001-0.0001% of the population) that would be con-
sidered appreciable as well as the associated uncertainty.
This appears to endorse Hattis et al [19]. ‘Straw Man’
proposal for a quantitative definition of the RfD, namely:
 “The daily dose rate that is expected (with 95%
confidence) to produce less than 1/100,000
incidence over background of a minimally adverse
response in a standard general population of mixed
ages and genders, or
 “The daily dose rate that is expected (with 95%
confidence) to produce less than 1/1,000 incidence
over background of a minimally adverse response in
a definable sensitive subpopulation.”
While there are no legally binding quantitative defini-
tions of desired level of protection for non-carcinogenic
chemicals, the ‘Straw Man’ proposal has come under de-
bate. There are experimental, statistical and mathematicallimitations to deriving risk estimates at the level of 1 in
100,000 additional cases with any meaningful degree of
certainty. It is clear that regardless of its exact value, the
desired level of protection will have to be extrapolated
from the observed data (animal experiments) by several
orders of magnitude. Many non-threshold dose–response
models fit the toxicity data equally well but differ vastly in
terms of effect estimates at low doses.
A detailed discussion of low level effects is beyond the
scope of this review. It should nonetheless be noted that
it is now widely recognised that even if the existence of
biological zero-effect levels is assumed, these cannot be
quantified, neither at an individual nor at a population
level [20]. Although often misunderstood, NOAELs can-
not be equated with zero-effect levels. They are also not
“natural constants” as their numerical value is strongly
influenced by the experimental design, such as the spa-
cing of doses, number of animals and the sensitivity of
the endpoint considered. In general, fewer tested doses
and lack of statistical power will produce higher NOAELs.
In some cases, NOAELs are associated with effect magni-
tudes as high as 25% (see the discussion in [21]). It has
also long been recognised that the degree of protection
achieved varies not only with the size of the factor but also
the slope of the log dose–response curve [22,23]. The
benchmark dose level (BMDL) has been proposed as an
alternative to the traditional NOAEL approach [24]. The
BMDL is defined as the lower statistical confidence limit
of the dose resulting in a predetermined response. It has
attracted interest because it accounts for the shape of the
dose–response curve and the quality of study design,
thereby providing an incentive to conduct better studies,
and it is not restricted to doses tested experimentally [25].
It has been proposed that linear extrapolation from an ob-
served point of departure such as a NOAEL or BMDL
may be the least uncertain method of assigning reasonable
upper bound estimates of risk for both cancer and non-
cancer endpoints [26,27].
In summary, although there is no legally binding quan-
titative definition of ‘appreciable risk’ or the desired level
of protection, it is generally accepted that it ought to be
of a magnitude equivalent to 0.001-0.0001% over back-
ground incidence, in line with Hattis’ “Straw Man pro-
posal”. Difficulties arise, however, as different methods
of deriving the dose corresponding to this response may
themselves yield estimates that differ by several orders of
magnitude.
Safety factors and adequate margin of safety
Because it would not be ethically acceptable to test tox-
icity on human populations, a safety factor of 100 was
originally proposed by Lehman and Fitzhugh [28] of the
US Food and Drug Administration. To derive a level con-
sidered safe for humans, the safety factor was combined
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oral administration of the substance of interest. A safety
factor of 100 was arbitrarily set, but was originally as-
sumed to cover interspecies (animal-to-human) variability,
and inter-individual (human-to-human) variability, which
allowed sensitive human populations to be compared with
healthy experimental animals. It was also assumed to pro-
tect against possible synergistic action of the many xeno-
biotics found in food. In June 1957, the Joint FAO/WHO
Expert Committee on Food Additives (JECFA) met in
Geneva to discuss the issue. The Committee stated that
“in the absence of any evidence to the contrary” an arbi-
trary factor of 100 applied to the maximum ineffective
dose in animals calculated in mg/kg bodyweight provided
an adequate margin of safety [29]. This margin of safety
was purported to allow for “any species difference in sus-
ceptibility, the numerical differences between the test ani-
mals and the human population exposed to the hazard,
the wider variety of complicating disease processes in the
human population, the difficulty of estimating the human
intake and the possibility of synergistic action among food
additives” [29].
Mixture effects
Sometime between the 1970s and the early 1980s, the
consideration of possible mixture effects within an overall
safety factor faded in favour of a division of the 100 factor
into two sub-factors of 10, each accounting for either
intra- or interspecies variability [30-32]. Even though it
was recognised that additive or synergistic effects needed
to be considered in the derivation of an ADI, the Joint
FAO/WHO Meeting on Pesticide Residues (JMPR) con-
cluded in 1981 that although there was a need for further
data on interactions of pesticides, the consideration of
mixtures did not require any change in the general princi-
ples for estimating ADIs. The rationale for this decision
was given by the following justifications [17]:
 “Not only could pesticides interact, but so could all
compounds (including those in food) to which man
could be exposed. This leads to unlimited
possibilities, and there is no special reason why the
interactions of pesticide residues (which are at very
low levels) should be highlighted as being of
particular concern;
 “Very little data on these interactions are available;
 “The data obtained from acute potentiation studies
are of little value in assessing ADIs for man.”
It is interesting to note that not the purported intrinsic
conservativeness of safety factors, but the complexity of
the issue and a lack of data were chosen as justifications
for discounting mixture effects. If the default overall
safety factor of 100 was originally intended to accountfor mixture effects, this intention has been abandoned
thirty years ago.
Towards chemical-specific adjustment factors
The International Programme on Chemical Safety (IPCS)
stated that the safety factor “is intended to provide an ad-
equate margin of safety for the consumer by assuming
that the human being is 10 times more sensitive than the
test animal and that the difference of sensitivity within the
human population is within a 10-fold range” [33]. This
statement effectively spells out hypotheses that have sub-
sequently been both subject to disputed interpretations
and have stimulated research efforts intended to confirm
its scientific basis. For environmental chemicals, a number
of additional factors were proposed to account for various
shortcomings in the experimental data being extrapolated
to a Tolerable Daily Intake (TDI) or RfD, such as inappro-
priate design, using acute or subchronic rather than
chronic data, or a lowest observable adverse effect level
(LOAEL) rather than a NOAEL, as well as other factors
such as severe or irreversible effects [22,34-36].
The further subdivision of the conventional 100-fold
safety factor according to two aspects of toxicity, toxico-
kinetics and toxicodynamics, was elaborated by Renwick
[36,37]. Renwick’s preliminary analysis of a few available
toxicokinetic and toxicodynamic differences between
species and within the human population for a few phar-
maceuticals and artificial sweeteners led him to consider
the default 10 × 10 factors not as a ‘worst-case’ but ra-
ther as an ‘adequate’ scenario. Overall safety factors be-
tween 1.2 and 7,500 were tentatively drawn and a factor
approaching 10,000 was suggested as more appropriate
when a particular subset of the population is thought to
be particularly sensitive [37]. In a subsequent article
from 1993 where the rationale for the subdivision of
each 10 sub-factor was elaborated, Renwick admitted
that the limited data presented would support applying a
10-fold factor to interspecies toxicokinetics alone [36].
He justified the introduction of a 4-fold factor for inter-
individual kinetic differences with reference to the obser-
vation that in healthy adults the coefficient of variation
in kinetic parameters for an artificial sweetener and six
pharmaceutical compounds was 80% or less for 5 of the
7 compounds. If a normal (Gaussian) distribution were
assumed to underlie these values, the 99th percentile for
a standard deviation of 80% would correspond to 2.9
times the mean value. The value of 4 was selected on
the basis of the limited size of the individual studies and
was supported by a more extensive review published by
Hattis et al. [38]. It was nonetheless recognised that
inter-individual differences in kinetics alone may greatly
exceed a 10-fold span.
With regards to inter-individual toxicodynamic differ-
ences, the default value of 2.5 for the sub-factor was
based on acute effects of pharmaceutical compounds in
healthy adults. Although data would have supported a
higher value, the default value was justified on the basis
that “inter-subject variability in specific drug receptor
sensitivity would be greater than less specific toxicological
phenomena” [36]. Although it was recognised that these
values were based on data obtained in healthy adults and
may therefore not apply to particularly sensitive groups
such as the elderly and the diseased, it was recommended
that specific health advice be given to potentially “at risk”
minorities, considering exposure to food additives and
contaminants. Further, Renwick [36] concluded that de-
fault values were chosen to fit the 100-fold overall factor
such that adoption of the proposed scheme “would not
require a cataclysmic re-evaluation of all possible toxi-
cants!”. In 1994, the scheme was adopted in modified
form by IPCS. IPCS considered toxicokinetic and
toxicodynamic inter-individual differences were similar
and the 10-fold factor inter-individual variability was
equally sub-divided between the two aspects (100.5 =
3.2) as illustrated in Figure 1 [39].
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championed to allow the replacement of individual de-
fault sub-factors by values derived from chemical spe-
cific data when available, and guidance for the use of
chemical or pathway-specific adjustments was subse-
quently drawn by the IPCS [40]. The use of toxicokinetic
and toxicodynamic preclinical and clinical data in humans
has been investigated for setting occupational exposure
limits for pharmaceutically active ingredients [41-43], as
100-fold uncertainty factor 
Interspecies 
differences 
10-fold 
Intraspecies 
differences 
10-fold 
Toxico-
kinetics 
100.6 =  
4 
Toxico-
dynamics
100.4 = 
2.5 
Toxico-
kinetics 
100.5 = 
3.2 
Toxico-
dynamics 
100.5 = 
3.2 Figure 1 Subdivision of the 100-fold default uncertainty factor
adopted by IPCS.well as natural compounds as probe substrates for the
cytochrome P450 (CYP) 1A2 to derive a pathway-specific
kinetic adjustment factor for human variability [44] (CYPs
are a large and diverse group of enzymes involved in the
metabolic oxidation of xenobiotics). These studies re-
cognised that the existence of two or more distinct gen-
etic forms (polymorphisms) of enzymes involved in
xenobiotic metabolism could give rise to multimodal
sensitivity distributions for human populations. In such
cases, the inter-individual toxicokinetic variability sub-
factor should be equal to the ratio of the furthermost tail
of the distribution (protecting 95 or 99% of the sensitive
subpopulation) and the median for normal healthy indi-
viduals. Whilst conceding that the default toxicokinetic
sub-factor for human variability (3.2) would not protect
sensitive subgroups such as neonates from chemicals
metabolised by CYP 1A2, Renwick et al. [44] nevertheless
recommended that a pathway-specific factor be derived
for healthy young adults, and sensitive subgroups pro-
tected by risk management measures. Alternatively, he
suggested that a constant proportion of the combined
population be used to derive an uncertainty or adjustment
factors in order to protect sensitive subgroups which can-
not be recognised by risk managers (as is the case with
polymorphisms, where most people would not be aware
of their specific genetic susceptibility). Nonetheless, it is
clear that the use of chemical or pathway-specific adjust-
ment factors, instead of a default uncertainty factor, could
yield greater as well as smaller overall adjustment factors.
In summary, the default values for the overall uncertainty
factor and its sub-components do not represent a worst-
case scenario, and were never intended to do so.
Current European guidance
The scientific validity of the default values of assessment
factors and sub-factors has been the subject of several
comprehensive reviews in the peer-reviewed literature
as well as reports in the grey literature. In the default
values recommended by the European Chemicals Agency
(ECHA) for use under the REACH Regulation are re-
produced together with values recommended by various
other agencies [45]. The recommendations of the Swedish
National Chemicals Inspectorate (KEMI) were not in-
cluded in the annex of the ECHA guidance but are
presented here. As the focus of this work is on oral expos-
ure, a factor that can be applied to extrapolate between
different routes of exposure has been omitted from this
table. It is interesting to note at this stage that ECHA rec-
ommends using an allometric scaling factor in combin-
ation with a sub-factor of 2.5 for toxicodynamics to
account for interspecies differences. As a result, the inter-
species subfactor may be greater or smaller than 10 de-
pending on the experimental animal species from which a
safe level is derived. KEMI and ECHA recommend the
use of an extra factor of up to 10 in cases where the data-
base from which a safe level in experimental animals is se-
lected is considered to not appropriately assess potential
effects on children [4,45] Table 1.
In this chronological perspective we were able to es-
tablish that the default uncertainty factor is no longer
intended to account for mixture effects, nor does it rep-
resent a worst-case scenario. However, later we will see
that it still holds sway in some unspoken assumptions
about the degree of protection afforded by these factors.
It is therefore interesting to critically review and update
the data used to justify the values for interspecies and
intraspecies or interindividual variability in the reports
summarised in Table 1. This is important in order to
gauge the degree of conservatism afforded by the default
100 assessment factor. Component subfactors are con-
sidered individually first, before attention is given to
their combination.
Interspecies variability
Allometric scaling
Interspecies differences in responses to toxic chemicals
may arise from differences in body size alone. This is
was also considered, and although its scientific merits
were recognised, the familiar metric of mg/kg body weight
was adopted for practical convenience [13,50]. Many
physiological functions correlate better with body surface
or caloric demand than with body weight. An allometric
equation raising the body weight to the power 0.75 or 0.67
for caloric demand or surface area, respectively, can be
used to calculate species-specific allometric scaling factors
for application to doses expressed in mg/kg body weight.
For common test species, estimates for these factors are
given in Table 2. Kalberlah and Schneider [3] reviewed
efforts to derive the allometric exponent, and this yielded
values between 0.42 and 0.97. They also found that ap-
proaches using caloric demand or surface area largely
produce similar results. On theoretical grounds, extrapola-
tions based on caloric demand are generally preferred to
those based on body surface [49]; clearance rates of
chemicals and other time-dependent parameters as well as
the consumption of nutrients appear to correlate with
body weight raised to the power of three quarters [51].
Watanabe et al. [52] reanalysed data used to derive coeffi-
cients of the allometric equation and found that scaling
according to caloric demand provided a better fit. In view
a
]
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Accordingly, NOAEL, LOAEL and BMDL as well as the
safe levels derived from these estimates are expressed in
mg/kg body weight/day. During the development of the
ADI concept, the dose metric of mg/body surface area
Table 1 Summary of default assessment factors used in hum
Assessment factors WHO-IPCS
[17,22,33,39]
USEPA [46] ECETOC [1
Database adequacy 1-10
LOAEL to NOAEL 3-10 10 3
Severity of Effect 1-10
Duration of exposure 10
Sub-chronic to chronic 2
Sub-acute to sub-chronic
Sub-acute to chronic 6
Interspecies 10 10
Toxicokinetics 4.0
Allometric scaling
Mouse 7
Rat 4
Monkey 2
Dog 2
toxicodynamics 2.5
Intraspecies 10 10 5
Toxicokinetics 3.16Toxicodynamics 3.16
Modifying factor ≤10of the variance in the data, they nevertheless advocated
scaling according to the more precautionary surface
area [21,52]. It should be stressed that these investiga-
tions were carried out considering the acute toxicity of
antitumour drugs. Agents such as these interfere with
n health risk assessment (adapted from ECHA 2008)
Danish
EPA [47]
UBA/BAuA
[3,48]
TNO/RIVM
[5,49]
KEMI [4] ECHA
Guidance [45]
1-100 1 1-5 1
10 1-10 3-10 3
1 1-10
2-3 10 3 2
2–3 10 8 3
6-7 50-100 24 6
10 10 10
4
7 7
4 4
2 or 4 2
2 1.4
2-3 2.5 2.5
10 25 10 10-16 10
8 3–53 3.16
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closely allometric scaling, but this may not hold true for
toxicants with other modes of action [51]. An extensive
review of drug metabolism suggested that if renal dis-
position correlates adequately with allometric scaling,
this may not be the case for hepatic metabolism [53]. It
has therefore been recommended that an additional
factor be applied to data from experimental animals to
extrapolate safe levels in humans, in addition to dose
extrapolation across species according to allometry [54].
Deviations from allometric rules
Brain weight and oxygen consumption also diverge from
allometric scaling and this may mean that humans are
more sensitive to neurotoxic effects than experimental
animals. Another interesting example of deviation from
the allometric rules is that of polychlorinated biphenyls
(PCBs) for which NOAEL values for rats, mice and
monkeys differed by several orders of magnitude [55].
Reproductive endpoints also depart from the allometric
principle. Compared to rodents, the male human has
relatively low sperm numbers and numbers of motile
sperm with respect to that required for fertility [3].
In addition to interspecies variations that can be
explained in terms of differences in size alone, there are
differences in susceptibility to toxic injury related to
species-specific toxicokinetic and toxicodynamic factors.
Table 2 Allometric scaling factors according to caloric
demand and surface area for common experimental
species
Test species Scaling factor for
caloric demand
Scaling factor for
surface area
Mice 7 14
Rats 4 6
Rabbits 2.4 3
Dogs 1.4 1.7Toxicokinetic interspecies differences
Schneider et al. [56] compared pharmacokinetic parame-
ters for the mouse, rat, guinea pig, hamster, cat, rabbit,
dog, monkeys and the human. Their literature search
yielded data for 71 substances and they calculated spe-
cies ratios that were in good agreement with allometric
scaling according to caloric demand. Griem et al. [57]
carried out an extensive review of in vitro data on the
enzymatic transformation of substances in the rat, mouse
and human for the liver, respiratory tract kidney and
gastrointestinal tract. Some differences in enzymatic trans-
formation of xenobiotics were observed between experi-
mental animals and humans. These differences between
species were not found to be systematically higher orlower for a given enzyme but rather enzymatic activity dif-
fered according to the organ system considered. For
example, there were no discernible differences in in vivo
CYP activity between rodents and humans, whereas
in vitro CYP activity was considerably higher in the lungs
of rodents compared to humans. An empirical model was
used to assess the relevance of species differences ob-
served in the liver in vitro for in vivo metabolism. Species
differences observed in vitro were accurately predicted to
persist in vivo for enzyme-substrate complexes with a low
intrinsic clearance (the ability of organs such as the liver
and kidney to metabolise or excrete a substrate). For
higher intrinsic clearance rates (approximately five times
the hepatic blood flow or higher), substrate transport in
the blood became the rate-determining factor and inter-
species ratios of hepatic clearance were in agreement with
allometric scaling according to metabolic rate. Walton
et al. [58-60] carried out literature searches of pharmaco-
kinetic and metabolism studies in humans and animals for
probe substrates of CYP1A2, glucuronidation and for
compounds excreted unchanged in urine. Mean clearance
ratios following oral absorption of CYP1A2 substrates
were 6.2 and 10.2 for the rat and the mouse, respectively,
compared to the human, evidently larger than the 4 de-
fault value assigned to the subfactor for toxicokinetic in-
terspecies differences or the allometric scaling factors for
those species [58]. The review of compounds excreted as
glucuronides uncovered important differences between
humans and test species, with some compounds excreted
unchanged in test species, but not in humans. Another
significant factor that would influence the internal dose
was the extent of enterohepatic recirculation. The ratios
of clearance values (the dose divided by the total systemic
dose) in humans compared to test animals for drugs that
were glucuronidated in humans varied from 38 for oxaze-
pam in the rat to 0.095 for zomepirac in the rabbit [59].
For compounds excreted unchanged primarily by renal
excretion in both the human and experimental animals
(following intravenous injection), ratios of plasma clear-
ance in animals compared to humans varied from 0.26 in
the dog for 1-aminocyclopropanecarboxylic acid to 35 in
the mouse for cefotetan. The extent of plasma protein
binding has a marked influence on tissue distribution and
rates of excretion particularly by glomerular filtration [60].
Toxicity also depends on the active form of the chemical,
depending on whether toxicity is due to the parent
compound, a highly reactive metabolite which disappears
rapidly, or a stable metabolite capable of entering the cir-
culation. Clewell et al. [61] used pharmacologically based
pharmacokinetic models where they applied mouse, rat
and human parameters. They found that interspecies dif-
ferences in toxicokinetics alone could exceed the default
interspecies factor of 10 by up to ten-fold depending on
the toxic form of the chemical.
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There is generally a paucity of data regarding differences
of sensitivity between species due to toxicodynamic pa-
rameters. A well known example of such variation is
that of the acute toxicity of 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD); differences of up to four orders of
magnitude in the median lethal dose (LD50) between
hamsters and guinea pigs were attributed to varying concen-
trations and functions of the intracellular arylhydrocarbon
receptor (AhR) [3].
There is therefore evidence that the sensitivity of experi-
mental animals to the toxicity of chemical substances can
deviate from allometric scaling and that there are also
toxicokinetic and toxicodynamic differences between
animals and humans that may render animals either more
or less sensitive than humans. To assess how frequently,
or for which proportion of chemicals an interspecies ex-
trapolation factor may exceed the default values it is ne-
cessary to analyse datasets for groups of chemicals rather
than individual substances or specific pathways. The fol-
lowing sections review the magnitude of interspecies dif-
ferences derived from such datasets.
Quantitative evaluation of interspecies differences
Two types of data have been used for the quantitative
evaluation of interspecies differences. Firstly, there are pre-
clinical data for pharmaceuticals in test animals and these
have been used to compare toxic doses with those derived
from human clinical data (summarised in Table 3). Sec-
ondly, comparisons of toxicity evaluations between animal
species have been made and these are presented in Table 4.
Comparisons of toxic or tolerable doses between ani-
mals and humans have been conducted mostly for anti-
neoplastic agents. There is considerable overlap between
the datasets used for these analyses. Further, this type of
data suffers from a number of limitations that were best
enunciated by Price et al. [69];
 Maximum tolerated doses (MTD) for anti-cancer
drugs in humans are by definition associated with
toxic effects in some subjects, and therefore cannot
easily be compared with NOAELs derived from
animal experiments where effects are usually less
obvious.
 Data were drawn from short-term studies of acute
toxicity rather than chronic exposure.
 The toxicological endpoints used across species or
across compounds may differ.
 Anti-cancer drugs are normally administered by
injection and do not reflect interspecies differences
in absorption from the gastro-intestinal tract or
first-pass metabolism in the liver. Many anti-neoplastic agents are direct-acting
compounds that target rapidly dividing cells and aretherefore not representative of the universe of
general chemicals.
 MTDs for chemotherapeutic drugs in humans are
derived from patients with advanced stages of
cancer who are likely to be more sensitive to toxic
effects than healthy adults.
 Dose metrics such as MTDs and NOAELs include
measurement error.
In addition to chemotherapeutic drugs, a couple of
studies analysed data for other pharmaceuticals and
Dourson and Stara [31] included two other studies, one
reporting values for the toxicity of poisonous metal com-
pounds and another listing data on the toxicity of a lim-
ited number of pesticides. Two main conclusions can be
drawn from the data presented in Table 3; smaller ani-
mals appear less sensitive than larger animals (medians
for ratios are generally in good agreement with allomet-
ric principles according to basal metabolic rate), and the
default value of 10 is likely to be exceeded for a signifi-
cant proportion of chemicals. The reported values for
the 95th percentiles for the distribution of interspecies
ratios indicate that variations between chemicals are far
greater than interspecies variations.
The rationale for considering differences in toxic re-
sponses between animal species is that their magnitude
is expected to be similar to the differences observed be-
tween animals and humans. The main advantage of this
type of dataset is that they include several classes of
chemicals and are therefore more representative of the
universe of chemicals. Table 4 illustrates again good
agreement between measures of central tendency (mean
or median) with allometric scaling, whilst measures of
spread such as range or percentile values demonstrate
large differences in the sensitivity of animal species from
chemical to chemical. Chemical-to-chemical variation
also appears to be heavily influenced by the endpoints
used as a basis for comparisons. Potency differences
based on LD50 were much smaller than the species-
species differences based on NOAELs. Calabrese and
Baldwin [72] applied a different approach to derive an
interspecies uncertainty factor of 26 (Table 4). They
assumed that susceptibility to toxic substances has an
evolutionary basis and is related to phylogenetic dis-
tance and used a large aquatic toxicity database, without
adjusting for allometry.
In summary, the level of conservatism afforded by the
default factor of 10 for interspecies differences depends
on the animal species that is considered for analysis.
The allometric scaling factor agrees reasonably well
with the median of all chemical-specific interspecies
factors. Thus, the allometric scaling factor will overesti-
mate interspecies differences for half of the chemicals
and underestimate it for the other half. For rodent
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Substances
dataset
Dose metric Species
Poisonous metal
compounds
Toxic doses Ratspecies routinely used in chemical hazard assessment,
the allometric scaling factors (Table 2) are relatively
close to 10, and this value may be exceeded for a sizeable
proportion of chemicals.
Intraspecies variability
Although not usually inbred, strains of laboratory ani-
mals are genetically fairly uniform and are bred to
18 chemotherapeutical
agents
Lethal Dose (LD)10 and
Maximum Tolerated Dose
(MTD)
Mouse, rat, h
monkey
10 pesticides (single
dose) and 12 pesticides
(repeated doses)
Various toxic doses Rat, dog, pig
horse, sheep
40 anticancer agents MTD Dogs, monke
107 pharmaceuticals (?) Toxicity indices 4 to 6 labora
species
25 chemotherapeutic
agents
LD10 and MTD Mouse, rat, h
monkey
26 pharmaceuticals Maximum therapeutic
equivalent dose and
toxicokinetic parameters
Up to 4 labo
species
63 anti-neoplastic drugs LD10, Toxic Dose Low
(TDL) and MTD
Rat, mouse, h
monkey
61 anti-neoplastic drugs LD10 and MTD Mouse, rat, dsing human and animal data
Results Reference
2.5<Toxic doseRat/Toxic
doseHuman<152
[31]
Geometric mean (GM) = 12produce responses with small variations. In contrast,
considerably larger inter-individual variation occurs
within the human general population. Genetic hetero-
geneity, age, gender and acquired susceptibility factors
such as disease state, diet, stress and previous exposures
are among the factors that will lead to marked differ-
ences in susceptibility to toxic injury. The scientific
basis for the intraspecies default factor of 10 has been
amster, dog, LD10 (mg/m2)/3 carries 5.9%
probability of exceeding MTDHuman
[62,63]
, calf, cow,
, steer
1.9<Acute non fatal doseAnimal/Acute
non fatal doseHuman<100
[31,64]
GM = 11.
0.58 <Chronic doseAnimal/Chronic
doseHuman<9.4
GM = 2.9.
ys MTD/10 carries a clinical risk human
toxicity of 3% (3 out of every 100
drugs)
[65]
tory animal Extrapolation of doses (mg/kg) from
white rats to man exaggerated
tolerable dose 5.5- to 40-fold
[66]
amster, dog, The predicted MTDHuman is
overestimated for 20% of agents
using 0.75 power (caloric demand)
scaling, less with body surface
scaling
[52]
ratory animal Scaling according to metabolic rate
underestimated risk to man in 59%
of cases
[67]
amster, dog, LD10 or TDLMouse/MTDhuman = 8.0
(P95 = 50.9)
[68]
LD10 or TDLHamster/MTDhuman = 7.6
(P95 = 52.1)
LD10 or TDLRat/MTDhuman = 2.6
(P95 = 21.7)
LD10 or TDLMonkey/MTDhuman = 2.4
(P95 = 15.3)
LD10 or TDLDog/MTDhuman = 1.2
(P95 = 7.0)
og, monkey LD10Mouse /MTDHuman >10 for 37%
compounds
[69]
LD10Rat /MTDHuman >10 for 19%
compounds
LD10Monkey /MTDHuman >10 for 5%
compounds
LD10Dog/MTDHuman >10 for 3%
compounds
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Substances dataset Dose metric Species
190 chemicals TD50 Mouse and rat
69 pesticides NOAEL Mouse, rat and dogscrutinised either by considering variations within the
healthy adult population or by considering the sensitiv-
ity of specific subsets of the population thought to be
particularly vulnerable to toxicity. Here, datasets and
studies examining inter-individual variability within the
healthy adult population are considered first, before
differences in sensitivity related to genetic polymor-
phisms in metabolising enzymes, due to gender, disease
or old age, and finally toxicokinetics in young children
are reviewed.
Binary interspecies
comparisons from
dozens to over 500
agents
Mostly LC50 Aquatic species
184 substances NOAEL Mouse, rat, dog
198 substances NOAEL Mouse, rat, dog
217 substances LD50 Mouse, hamster, guinea
pig, rat, cat, rabbit,
monkey dog
216 pesticides NOAEL Mouse, rat, dog
58 compounds NOAEL and Critical
Effect Dose (CED)
Mouse, ratsing only animal data
Results Reference
Median TD50Mouse/TD50Rat ratio = 2.4 [70]
20% of ratios exceeded 10
NOAELRat /NOAELDog : 1.58 (0.99-2.24) [71]
NOAELMouse /NOAELRat : 3.87 (2.24-6.32)
NOAELMouse /NOAELDog : 7.07 (3.53-13.42)Inter-individual variability in healthy adults
The only study investigating the overall inter-individual
variability of healthy adults is actually based on rats ra-
ther than humans. Dourson and Stara [31] used a data
set from Weil [75] with dose–response slopes for 490
acute lethality tests of carcinogenic agents in rats to as-
sess the protection afforded by an intraspecies factor of
10. The resulting distribution of adjustment factors (re-
quired to scale down a median response by three probits
to correspond to 0.13% mortality) suggested that for 8%
Orders-within-Classes Extrapolation [72]
Weighted mean of uncertainty factor (UF) prediction
interval (PI): 26 (95% PI), 35 (99% PI)
Upper 95% UFs: 65 (95% PI), 88 (99% PI)
NOAELRat /NOAELDog : 1.3 (P95 =18.8) [49]
NOAELMouse /NOAELRat : 4.2 (P95 = 73.9)
NOAELMouse / NOAELDog : 6.4 (P95 = 124.6)
NOAELRat /NOAELDog : 2.3 (P95 =27) [73]
NOAELMouse /NOAELRat : 3.2 (P95 = 37)
NOAELMouse /NOAELDog : 5.9 (P95 = 50)
LD50Mouse/LD50Rat= 0.86 (P95 = 2.52)
LD50Hamster/LD50Rat= 1.2 (P95 = 1.33)
LD50Guinea pig/LD50Rat= 0.71
(P95 = 2.96) [68]
LD50Cat/LD50Rat= 0.31 (P95 = 1.47)
LD50Rabbit/LD50Rat= 0.76 (P95 = 2.46)
LD50Monkey/LD50Rat= 0.63 (P95 = 0.88)
LD50Dog/LD50Rat= 0.82 (P95 = 4.87)
NOAELMouse/NOAELRat = 2.22 (P95 = 24.2)NOAELRat/
NOAELDog = 1.70 (P95 = 16.6)
[68]
NOAELMouse/NOAELDog = 6.00 (P95 = 44.8)
NOAELMouse/NOAELRat : P95 = 15.5; GSD = 3.4 [74]
CEDMouse /CEDRat : P95 = 5.6
Default value of 10 corresponds to 49th percentile and
71st percentile of mouse to human and rat to human
distributions respectively
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than 10 would be required. The authors acknowledged
several limitations to their approach, particularly the use
of animal data and the use of LD50s rather than NOAELs.
Other analyses of data related to inter-individual differ-
ences have considered toxicokinetic variation and toxico-
dynamic variation separately.
Inter-individual toxicokinetic variation
Available datasets related to toxicokinetic parameters in
humans are generally restricted to pharmaceuticals, oc-
cupational exposures, and some food additives. An early
dataset often referred to is that of Hattis et al. [38]. Studies
(mostly from 1979–1985) which contained individual hu-
man data on pharmacokinetic parameters in at least five
healthy adults for 49 chemicals (pharmaceuticals) were re-
trieved from the scientific literature. The median and 95%
range of all geometric standard deviations (GSDs) were
reported for each toxicokinetic parameter in two subse-
quent papers [76,77]. While the medians indicate that the
default value of 3.2 for inter-individual toxicokinetics
(Figure 1) would be sufficient for healthy adults for 50% of
chemicals, the upper limit value of the 95% ranges suggest
this may not be the case for all chemicals.
Renwick and Lazarus [78] carried out a similar review
and found toxicokinetic data for 60 compounds. If one
assumes that toxicokinetic inter-individual variability is
log-normally distributed, about 9,000 persons per mil-
lion would not be protected by the default value of 3.2.
Both datasets were combined and extended and the
combined database is freely available (http://www2.clarku.
edu/faculty/dhattis/#Web Site Description). It includes
data from the peer-reviewed scientific literature as well as
some supplied by the US EPA [79]. Figure six in that paper
again shows that if the medians of Log10(GSD) indicate
that the default value of 3.2 would be sufficient for half of
all chemicals, their 10-90% range suggest it would not be
sufficient when all chemicals are considered.
In an effort to derive uncertainty factors for specific
metabolic pathways, Dorne et al. [80] presented the results
of several literature reviews of human variability in 14 of
the main routes of metabolism including phase I enzymes,
phase II enzymes and renal excretion. Ranging from 1.6 to
2.7, the pathway-specific uncertainty factors that protect
99% of the healthy adult population were all smaller than
3.2, when monomorphic pathways, where a gene for a
specific enzyme is found in only one form throughout the
human species, are considered. However, this was not the
case for polymorphic pathways and genetic polymor-
phisms are discussed as part of sensitive subgroups.
Inter-individual toxicodynamic variation
This subfactor (3.2) is intended to allow for inter-
individual differences in response to the active form ofthe compound in the systemic circulation. Data sup-
porting toxicodynamic variability therefore requires separ-
ation from kinetic variability. A particular difficulty in
ascertaining toxicodynamic variation experimentally is
that it would ideally require precise measures of the
dose delivered at the target site and this is more readily
achieved in vitro, ex vivo or by pharmacologically based
pharmacokinetic (PBPK) modelling. Nonetheless, the
earliest dataset on toxicodynamic variability was assem-
bled by Renwick and Lazarus [78] who identified in vivo
plasma concentration-response data for 49 compounds.
Much of the data was for the clinical treatment of pa-
tients and disease and aging processes may have con-
tributed to variability. The estimated number of people
not covered by the 3.2 default value for inter-individual
toxicodynamic variation approached 19,000 per million
assuming a lognormal distribution, well above a desired
level of protection of 1 per 100,000.
The database described above also contains observa-
tions of systemic pharmacodynamic variability for 13
chemicals (Table VI in Hattis et al. [79]). Many of the
Log10(GSD) (13 out of 21 toxicodynamic parameters)
and most of their 5-95% range (19 of 21 toxicodynamic
parameters) exceeded 0.2 suggesting that a factor greater
than the default value of 3.2 would be needed to account
for toxicodynamic intraspecies variability. An update of
this database included 41 data groups (measurement of
a particular parameter for a particular chemical) relating
a response or physiological parameter to the internal
concentration after systemic delivery [81]. The 90th per-
centiles of Log10(GSD) of these data was approximately
0.6 suggesting that a 10-fold factor may be justified for
pharmacodynamic variability alone in some cases. The
authors found that pharmacodynamic variability is gen-
erally larger than pharmacokinetic variability.
Degree of protection from the intraspecies variation default
factor
From both the databases described in the previous sec-
tions, the proportion of healthy adults that fall into the
range of 10 for inter-individual variability was estimated.
Assuming that inter-individual variability is log-normally
distributed, Renwick and Lazarus [78] expected that 162
people per million would not be covered by the default
uncertainty factor.
From their database, Hattis et al. [82] estimated an
overall inter-individual variability intended to cover sev-
eral types of exposures (e.g. inhalation, ingestion) and
effects (chronic or acute). The authors estimated the
fraction of people that might show a response at one
tenth of the dose that produces a response in 5% of ex-
posed people. The Hattis database also includes some
variability in uptake that arguably ought to be accounted
for in exposure assessment rather than hazard assessment
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nearly 8 people in 100,000 would respond to chronic oral
exposure based on perfect drug compliance or about 2
people in 10,000 based on chronic ingestion of a toxicant
(includes variability in ingestion behaviour). When consid-
ering 95% of chemicals, these values increase to 2 and 3 in
every 1,000 people respectively.
It therefore becomes apparent that the default uncer-
tainty factor for intraspecies variability falls short of the
level of protection aspired to in the ‘Straw Man Pro-
posal’ (less than 1/100,000 incidence over background
with 95% confidence of a minimally adverse response in
a standard general population of mixed ages and gen-
ders) even when considering exclusively the variability in
healthy adults [19]. Further, Hattis et al. [82] enunciate a
number of caveats and limitations with the database and
methods to quantify variability;
 The toxicity database is assumed to be
representative of the universe of chemicals.
 Toxicological parameters for susceptibility are
assumed to follow a unimodal Log-normal
distribution, however it may not be the case, e.g.
when subgroups of the population are particularly
sensitive.
 Multiplicative approaches also assume independence
of each factor contributing to overall variability.
Interdependence of various parameters cannot be
excluded and could significantly modify expected
fraction of people at the extreme tails of population
distribution.
 Distributions of variability also include variability
due to measurement error.
Inter-individual variability in susceptible subgroups
The susceptibility of specific population subgroups to the
toxic effects of certain chemicals potentially gives rise to
multimodal distributions and this contradicts the assump-
tion of unimodality made in the analyses summarised
above. The aim is then to protect a reasonable proportion
of this sensitive subgroup, and the intraspecies variability
factor ought to extend the median for the general popula-
tion to the percentile of the sensitive subgroup to be
protected (see Figure 2).
Gender differences
The physiological distinctions between men and women
in terms of body weight, tidal volume, water and fat con-
tent are relatively small when normalised according to
body weight [48]. Nonetheless, differences in lean body
mass, percent body fat and to some extent plasma protein
concentrations result in variations in volumes of distribu-
tion, observed to be consistent with the hydrophilicity or
lipophilicity of compounds and gender-dimorphisms in fatcontent and lean body mass [83]. Gastric pH can influence
the absorption of weak acids and bases ingested. Women
secrete less gastric acid and have a shorter gastric empty-
ing time. Gastric emptying time is also influenced by sex
hormones, particularly during pregnancy and following
use of pharmaceutical hormones [83]. Gender disparity
has been observed in some Phase I metabolic P450 isoen-
zymes such as CYP1A2, CYP3A4, CYP2D6, CYP2C19
and is thought to arise from differences in sex hormones,
body weight, body water content and diet [61]. Pregnancy
influences many physiological parameters such as cardiac
output that will in turn influence elimination processes
such as the glomerular filtration rate. Lactational excre-
tion of lipophilic compounds is a major gender-specific
elimination route, as well as a route of exposure for neo-
nates [61]. Krasovskii [66] reports that the toxicity of 149
substances differed by 2- to 3-fold between male and fe-
male rats. Greater toxicodynamic differences are expected
to result if the mode-of-action of a substance affects sex-
specific differences such as the regulation of hormones or
specific damage to the sex organs [3]. Such differences are
generally addressed by the design of experimental studies
rather than multiplication by a factor.
Genetic polymorphisms
Calabrese’s [84] early attempt to characterise human
inter-individual variability suggested that genetically deter-
mined biochemical differences could result in variability
spanning several orders of magnitude. Polymorphisms
appear to be more frequent in genes encoding xenobiotic
metabolising enzymes than in other genes. It is hypo-
thesised that this may be due to the fact that the former
evolved as an adaptive response to the environment. This
in turn results in sometimes large ethnic differences in the
distribution of specific genotypes [4]. Accordingly, most of
the research in this area has focused on polymorphic
enzymes involved in xenobiotic metabolism but it is
increasingly recognised that genes involved in host
(toxicodynamic) responses to chemical stressors can
also be polymorphic.
Dorne et al. [80] derived pathway-specific uncertainty
factors including some polymorphic metabolic pathways
and found that inter-individual variability factors of up to
26 (CYP2C19), 52 (CYP2D6) and 5.2 (N-acetyltransferases)
would be necessary to protect 99% of poor metabolisers
and slow acetylators. The frequency of specific polymor-
phisms differs between ethnic groups and this led Dorne to
assign different pathway-specific uncertainty factors in
different ethnic groups [80]. Recent reviews of polymor-
phisms in metabolism genes and host defence enzymes
have been carried out [85,86]. For six phase I and phase II
enzymes, information about the influence of the polymor-
phisms on enzyme function was incorporated with geno-
type frequency in different ethnic populations to generate
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data to the 1st or 99th percentile of the sensitive sub-
group generally exceeded the default sub-factor for
inter-individual variability of 3.2 with values reaching
90-fold [85].
Moreover, Dorne and Papadopoulos [87] reviewed 200
studies of toxicokinetic interactions such as enzyme induc-
tion or inhibition for therapeutic doses of major probe sub-
strates of polymorphic CYPs. The authors’ conclusion was
that the default intraspecies subfactor for toxicokinetic dif-
ferences did not cater for toxicokinetic interactions.
It should nonetheless be noted that these differences
in enzymatic activity will not necessarily be reflected in
internal doses due to compensating metabolic pathways
related to overlapping substrate specificity and other
toxicokinetic parameters. PBPK modelling is required to
predict the variability of the resulting internal doses. Ap-
plied to warfarin and parathion, this approach yielded a
95th percentile to median ratio of 3.4 for parathion and a
99th percentile to median ratio of 26 for warfarin [88], im-
plying uncertainty factors exceeding the default subfactor
Figure 2 Derivation of intraspecies uncertainty factor from a unimodof 3.2 for inter-individual variabibility in toxicokinetics.
However, it is obvious that this approach requires simpli-
fying assumptions in relation to the relative contribution
of multiple enzymatic systems to metabolism and the ex-
tent of inhibition or induction of these pathways due to
co-exposures and other environmental factors [89], and
accordingly the outcome of uncertainty factor estimations
should be regarded with caution.
Differences in health-impaired and elderly people
Ageing affects the efficiency of metabolism and the elim-
ination of xenobiotics. In principle, this could result in a
higher sensitivity of elderly people to substances. Particu-
larly, decreases in circulatory efficiency may conceivably
compromise the effectiveness with which a compound is
distributed in the body. Elderly people are also more likely
to be affected by chronic health impairment and excess
weight. It is well established that disease can affect the
disposition of xenobiotics. Chronic Obstructive Pulmon-
ary Disease is associated with alterations of cardiac out-
put. Heart, kidney and liver disease will expectedly also
al parameter or from a bimodal parameter.
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Obesity is accompanied by increased blood volume and
cardiac output. There is a correlation between obesity and
type II diabetes, itself associated with reduced glomerular
filtration rates. Moreover, sensitivity to harmful substances
is expected to be modified not only when metabolic pro-
cesses are altered but also when the target organ of the
toxic effect is affected by disease [3]. Furthermore there is
a possibility of toxicokinetic interaction between envir-
onmental contaminants and therapeutic drugs adminis-
tered to health-impaired individuals. Ginsberg et al. [91]
reviewed the literature on therapeutic drug clearance in
elderly individuals and found that the half-life of drugs
metabolised by hepatic CYP enzymes or via renal elim-
ination is typically 50-75% longer in individuals over 65
years of age compared to younger adults. Thompson
et al. [90] compiled a database of physiological param-
eter values reported in the peer-reviewed literature for
healthy and health-impaired elderly (65 years of age or
older) freely available from the USEPA website (http://
cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=201924).
Meanwhile, elderly people may also exhibit higher
toxicodynamic sensitivity and therefore an intensifica-
tion of the adverse response to foreign substances [3].
Skowronski and Abdel-Rahman [92] compared toxico-
kinetic and toxicodynamic differences between healthy
adults and geriatrics for six pharmaceuticals and found
composite factors were all below the default value of 10
for inter-individual variation. Naumann et al. [42] com-
piled toxicokinetic and toxicodynamic data on drugs
from five different therapeutic classes and calculated ad-
justment ratios for various sensitive subgroups includ-
ing the health-impaired and the elderly. Their data
show that chemical-specific adjustment factors can be
both smaller or greater than default sub-factors, but
tend to exceed these default values more often in the
health-impaired than the healthy elderly. Dorne et al.
[80] calculated pathway-specific uncertainty factors for
the elderly subgroup and demonstrated that the toxico-
kinetic intraspecies subfactor of 3.2 is too small to
account for the observed variability. A distributional
analysis of the more recent and extensive databases now
available is warranted to better characterise the protec-
tion afforded to elderly and /or health-impaired people
by the default factor.
Children, infants and neonates
The sensitivity of children relative to adults has been the
subject of some debate in the United States where the
protection of children’s health was specifically included
in the 1996 Food Quality and Protection Act (U.S. Food
and Drug Administration 1996). The issue under discus-
sion was whether the protection of children requires an
additional uncertainty factor of 10. An important pointto consider is whether young animals were exposed in
the study from which a safe level is derived. This is not
the case in routine validated experimental protocols for
chronic or sub-chronic toxicity. When animals are ex-
posed during critical periods of development such as the
prenatal or neonatal period, the ability to predict their
susceptibility depends on the adequacy of the animal
model. Qualitative comparisons of the maturation of
metabolic processes in the rat and the human have been
published [78]. Similarly to humans, animal neonates
show slower clearance and longer chemical half-lives
than adult animals but there are also differences in the
rate of maturation of various Phase I or Phase II enzym-
atic processes and renal function between species. This
can equally be said of fetal exposure and cross-species
comparisons are typically equally lacking [93]. Dorne
et al. [80] calculated some pathway-specific uncertainty
factors for children and neonates. All pathway-specific
uncertainty factors derived for neonates were above the
default value for the intraspecies toxicokinetic subfactor
of 3.2 [80]. There are also suggestions that obesity may
lead to bimodal distributions of body weight for a given
age group of children [94].
Developmental effects that can result from exposures
during critical windows of development cannot be pre-
dicted, let alone extrapolated, from toxicity observed in
adult animals. Nonetheless, children are not generally
systematically more sensitive than adults to chemical ex-
posures. Charnley and Putzrath [95] updated a summary
of studies of the effects of age on chemically induced
carcinogenesis in rodents published in the report of the
American National Research Council ‘Pesticides in the
diets of Infants and Children’ [96]. Their analysis found
that younger animals were more susceptible in 37% of
studies whereas older animals were more susceptible in
53% of studies. The biological basis for the sensitivity of
children and toxicokinetic differences between children
and adults has been comprehensively reviewed [93,97].
The maturation of metabolic processes is of particular
interest and most of these processes are reasonably ma-
ture by 6 months of age and completely functional by 1
year. A number of studies have investigated the safety
afforded to children by the default value for the intra-
species factor either by considering ratios between
young and adult animals or those of toxicokinetic and
to a lesser extent toxicodynamic parameters between
human adults and children. The results of those studies
are summarised in Table 5 and suggest that the neonatal
period is particularly sensitive. Several studies indicate
that default values for the intraspecies variation factor
or its toxicokinetic component would be too small for
about 30% of chemicals in the first two months of life.
This proportion increases to 70% when considering the
first week of premature babies.
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Substances
dataset
Dose metric Stage of development
Animal data
238 chemicals LD50 Adult and newborn
mammals
18 industrial
chemicals
pNOAEL Young and newborn rats
(postnatal days 4 to 21)
Human data
15 anticancer
drugs
MTD Adults and children
24 drugs Hepatic clearance (Cl)
or half-life (HL)
Adults and newborns
22 substances Toxicokinetic
parameters
Adults and children and/or
newborns
313 substances LD50 Adults and childrenMultiplication of subfactors
On the premise that subfactors are conservative worst-
case scenarios, it has been argued that their multiplica-
tion results in overly conservative estimates of safe levels
for humans [103]. Probabilistic alternatives to the deter-
ministic default factor approach were proposed to help
quantify the propagation of uncertainty and level of con-
servatism. Rather than using single default values, distri-
butions of ratios allow statements about non-observed
combinations and therefore are used in extrapolating
from animals to healthy adult and then to sensitive indi-
viduals. The method requires an accurate characterisa-
tion of the distribution of each assessment subfactor and
of possible correlations between them. It is generally as-
sumed that all factors are independent and that this
premise is sufficiently conservative. As we have stressed
earlier, these distributions assume comparability between
different types of dose levels, acute and chronic toxicity
as well as endpoints. These assumptions have not been
subjected to scientific scrutiny. Rather, they are prag-
matic approaches that make use of the best available
(mostly
pharmaceuticals)
6 drugs Toxicokinetic
parameters (one
toxicodynamic)
Adult and children
44 drugs Half-life Adult and children in
different age groupsetween adult and the young
Results Reference
Median LD50Adult/LD50Newborn = 2.6 [70]
14% of ratios exceeded 10
NOAELYoung/NOAELNewborn < 5 for 17
of 18 chemicals
[98]
1.3 < Mean MTDChild/MTDAdult <4.1 [99], ratio of equivalent doses
in mg/kg calculated by
Dourson et al. [100]
Cl or HLNewborn/ Cl or HLAdult > 3.2
for 33% of drugs
[101], ratios calculated by
Dourson et al. [100]
3.2 subfactor for toxicokinetics
intraspecies differences adjusts the
adult parameter to that of the infant
or child for 91% of substances.
[78] as calculated by Dourson
et al. [100]
14% of LD50 /LD50 > 10 [102]data. The simplest probabilistic approach is by using
Monte Carlo simulation techniques [49,104]. However,
by using hypothetical case studies, Carlson-Lynch et al.
[105] demonstrated that the choice of distribution for
the uncertainty factors can yield quantitatively different
results and qualitatively different interpretations. Prob-
abilistic approaches have also been used to assess the
level of conservativeness of the default 100 uncertainty
factor and results of such analysis are shown in. The re-
sults of the various approaches vary, predicting that the
default uncertainty factor of 100 would be exceeded for
less than 5% to nearly 40% of chemicals when derived
from experimental data in rodents. The choice of distri-
bution for the subfactors has therefore a great influence.
A critical evaluation of these choices should consider
whether the distribution was based on data as opposed to
a theoretical distribution, whether these data were derived
from humans or animals only, and whether adjustment
for allometric scaling was included. The only analysis that
would meet these requirements is that of [106] for which
we calculated that the default uncertainty factor of 100
Adult Child
Ratio of mean adult parameter to
lower 95% value of children varied
between 0.6-3.7.
[92]
Composite ratios all below 10
Proportion of children whose half-life
exceed 3.2-fold the adult mean
value;
[94]
0–1 week premature: 70%
0–1 week full term: 26%
1 week- 2 months: 27%
2 months-18 years: 0%
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http://www.ehjournal.net/content/12/1/53would be exceeded by 15-20% of chemicals if a safe level
for human were to be extrapolated from experimental
data in the rat (Table 6). When considering that sensi-
tive subgroups and multimodal distributions of inter-
individual sensitivity have not been taken into account
in those analyses, an unwavering belief in the undue
conservativeness of the default uncertainty factor ap-
pears ill-founded Table 6.
Attempts to give uncertainty factors a probabilistic inter-
pretation in terms of response ratios of random chemicals
have been argued by some to be ill-conditioned, and Cooke
[111] proposed alternative statistical approaches for deriv-
ing safe levels such as non-continuous Bayesian belief nets.
This would result in new chemicals being assessed on the
basis of previous assessments for existing chemicals. Goble
and Hattis [50] pointed out that past choices need to
be reassessed and potentially revised in view of the level
of risk that is considered acceptable to the general pub-
lic. In accord with these authors, our review demon-
strates that the most serious challenge of probabilistic
approaches is the representativeness of the distributions
from which samples are drawn. For obvious ethical rea-
sons, human studies of the pharmacodynamics or kinet-
ics of chemicals do not include vulnerable populations.
The same argument can be used in relation to the repre-
sentativeness of substances investigated compared to the
universe of chemicals the general population is exposed
to. However, it is unknown whether the bias introduced
by the sets of chemicals in the various databases leads to
an underestimation or an overestimation of risks.
Sufficient protection against mixture effects?
There has been much progress in the thinking of regula-
tory bodies about combination effects and its implications
for the traditional risk assessment paradigm. One import-
ant achievement is the acknowledgement by key European
scientific committees that NOAELs cannot be equated
with zero effect levels (SCHENIR VKM). However, it ap-
pears that the implications of this recognition for cumula-
tive risk assessment are not fully appreciated. With an
emphasis on human health effects, the EU Scientific Com-
mittees stated: “…, if the intended level of protection is
achieved for each individual substance, the level of con-
cern for mixtures of dissimilarly acting substances should
be assumed as negligible.” This statement is open to inter-
pretation, but seems to suggest that ADIs and similar
health-based guidance values, together with the corre-
sponding UFs, also protect against mixture effects.
We are now in a position to examine the two tacit as-
sumptions that underlie this statement, namely that ADI
or similar health-based guidance values generally repre-
sent zero effect levels, and that the diversity of chemicals
which make up human exposures act in strictly inde-
pendent ways, according to the stochastic principles ofthe mixture concept of independent action. Only if both
assumptions can be shown to be realistic, are combin-
ation effects not to be expected. In such a situation, the
protection achieved for single substances by using UFs
for ADI setting also safeguards against mixture effects.
Our examination of the literature has shown that
health-based guidance values cannot be demonstrated to
represent absolute zero effect levels, as is recognised by
the intended level of protection enunciated in the ‘Straw
Man’ proposal. Even if we assume that the mixture as-
sessment concept of independent action is applicable to
the multitude of chemicals relevant to human exposures,
certain risks may arise from small effects associated with
single chemicals which might cumulate according to sto-
chastic principles. For example, independent action as-
sumes that 100 chemicals each associated with an effect
of 0.01% will produce a combination effect of 0.97%.
Considering the diversity of chemicals human beings
are exposed to, it is intuitively appealing to assume that
independent action, with its assumptions about different
mechanisms and modes of action, should be generally
applicable for an assessment of mixture effects. However,
the applicability of independent action to mammalian or-
ganisms and cells has yet to be demonstrated. There is no
case described in the literature, where independent action
produced valid descriptions of combinations of chemicals
that produce shared toxic effects by different mechanisms
[12]. All the available evidence points in the opposite dir-
ection: independent action consistently underestimated
the combined effects of various chemicals with different
mechanisms. These findings have led many international
bodies to recommend the use of dose addition as the de-
fault concept (IPCS 2009). This was also supported by the
Scientific Committees.
Discussion
The evidence analysed in the preceding sections shows
that default uncertainty factors do not represent worst-
case scenarios and were not intended to do so. The
scheme originally proposed by Renwick [37] was sug-
gested to represent an adequate scenario in most but
not all cases. Two conclusions can be drawn from our
analysis. The first is that due to intractable ethical issues
about testing in humans, the database on which the ad-
equacy of the uncertainty factors can be judged is neces-
sarily poor. This introduces uncertainty and whether this
may lead to uncertainty factors that overestimate or
underestimate the risk to humans can only be speculated
upon but not scientifically proven. Secondly, the data
available does not support an unwavering belief in the
purported conservativeness of the overall default uncer-
tainty factor of 100.
In a regulatory context, where the replacement of de-
fault uncertainty factors by chemical- or pathway-specific
Table 6 Probabilistic multiplication of subfactors
Reference Database used Distribution parameters Results
Sheehan et al. 1990 [70]
Interspecies variation Ratios of tumour incidences (TD50s) for 190
chemicals in mice and rats
Median = 2.6
Intraspecies variation Ratios of acute lethality (LD50s) for adult and
newborn mammals for 238 chemicals
Median = 2.4
Overall assessment Values exceeding 100: 11.8%
predicted, 10% observed
Baird et al. 1996 [107]
Interspecies variation 69 pesticides tested in different animal species,
allometrically adjusted for body surface (Dourson
et al. 1992)
Median = AS1
GSD = 5
Intraspecies variation Probit dose–response slopes from 490 acute
lethality experiments using rats [75], assuming two
different levels of protection;
Basic approach:
Median = 2.7
GSD = 2.3
Basic approach: 1/100,000 Alternative approach:
Alternative approach: 1/1,000 Median = 5.3
GSD = 1.4
Overall assessment RfDs or RfCs for 126 compounds with NOAELs from
chronic bioassays in IRIS database
Basic approach: Fraction of RfDs within the lower
5% of distribution of potential
threshold values2 ;
Median = AS x 3 All: 56%
P95 = AS x 50 Mice: 23%
P99 = AS x 220 Rats: 39%
Alternative approach: Dogs: 98%
Median = AS x 5
P95 = AS x 63
P99 = AS x 194
Vermeire et al. 1999 ; Vermeire et al. 2001 [5,49]
Interspecies variation 184 substances tested in mice, rats and dogs GM = AS Factor 12 (4 for allometric scaling
x 3 for remaining uncertainty)
coincides with 73rd percentile.
GSD = 4.5
P95 = AS x 19
P99 = AS x 65
Intraspecies variation Theoretical, to be consistent with default factor 10,
P99 = 10 [108]
Median = 1 + 3
GSD = 1.6
Overall assessment GM = AS x 4 Percentile of the default factor
100: 79% (NOAEL in mouse), 88%
(NOAEL in rat)3
GSD = 4.7
P95 = AS x 53
Gaylor and Kodell 2000 [109]
Interspecies variation Binary aquatic interspecies comparisons from
dozens to over 500 agents [72]
Median = 1
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Intraspecies variation Probit dose–response slopes from 490 acute
lethality experiments using rats [75] adapted byfactors is encouraged, default uncertainty factors that
represent reasonable worst-case scenarios would provide
an incentive to generate better (chemical- or pathway-
specific) data. We believe this is not currently the case
and a revision of the current default uncertainty factors
deserves consideration.
Dourson and Stara [31]
Overall assessment
Schneider et al. 2005 [106]
Interspecies variation 63 antineoplastic agents in humans and five
different animal species [68]
Intraspecies variation Human database for predominantly healthy adults
developed by Hattis et al. [79]
Overall assessment Our own calculation
Hasegawa et al. 2010 [110]
Interspecies variation 63 antineoplastic agents in humans and five
different animal species adapted from [68]
Intraspecies variation Rat young/newborn NOAEL ratios for 18 industrial
chemicals [98]
Overall assessment
References
1 Allometric scaling factor according to body surface area (mouse = 14, rat = 6).
2 For 231 RfDs including some derived from LOAELs and/or sub-chronic bioassays.
3 Allometric scaling factors based on caloric demand were used.GSD = 1.66
Median = 1 Default value of 10 corresponds
to the 92nd percentileThe level of conservatism (or otherwise) of uncertainty
factors can only be considered in relation to a defined
level of protection. Absolute zero-effect thresholds for
the human population cannot be empirically determined.
There is therefore a need to decide what constitutes an
appreciable risk or the desired level of protection. This
GSD = 1.64
Median = 1
GSD = 2.33
P95 = 46
P99 = 230
GM = AS x 0.97
GSD = 3.45
P95 = AS x 6.7
P99 = AS x 15
GM = 3.8
GSD = 4.3
P95 = 44
P99 = 117
GM = AS x 3.7 Proportion of substances for
which the default factor 100
would not be exceeded:
GSD = 5.4 AS based on caloric demand;
76% (mouse), 85% (rat)
P95 = AS x 82 AS based on surface area; 64%
(mouse), 79% (rat)
P99 = AS x 295
GM = AS
GSD = 3.23
P95 = 48.2 (mice)
P95 = 27.5 (rats)
GM = 3
GSD = 1.38
P95 = 5.09
P95 = 155 (mice)
P95 = 88.7 (rats)
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considerable uncertainty associated with the extrapola-
tions from observed effects in experimental animals to
small effect magnitudes, often over several orders of
magnitude. It therefore follows that statements about
the conservativeness of uncertainty factors, the safety of
chemicals or mixtures invariably withhold hidden be-
liefs and value judgments. These need to be explicitly
stated for an intelligent debate about the desired values
attributed to default uncertainty factors to take place.
This has important implications for mixture risk assess-
ment, particularly in the case where independent action is
presumed. If absolute zero-effect threshold cannot be
demonstrated in the human population, we do not concur
that the combined effect(s) of chemicals with independent
modes-of-action below levels derived to be ‘safe’ for single
substances should be assumed to be negligible. The as-
sessment of such potential effects requires knowledge of
the exposure to all chemicals during an individual’s life-
time, (now often referred to as the exposome) and this
knowledge is at present generally lacking. This knowledge
gap was recognised by the Scientific Committees in their
opinion and by the European Commission in its recent
communication. We further argue that this incomplete
picture would impede the prioritisation of mixtures of
concern as recommended by the Commission. We there-
fore contend that precautionary regulation should provide
an incentive to generate better data and recommend that
a pragmatic approach is taken to mixture risk assessment.
In addition to detailed assessments of mixtures identified
as ‘of concern’, building additional safety in single chemical
risk assessment, whether in the form of an additional un-
certainty factor, larger margins of safety or exposure or
similar approaches, should be considered by the ad hoc
working group to be established by the European Com-
mission as a default for all substances until better know-
ledge of other relevant exposures and information about
the mode-of-action can be ascertained.
Conclusions
The present review demonstrates unequivocally that as-
suming that default uncertainty factors are overly conser-
vative worst-case scenarios that could account both for the
lack of statistical power in animal experiments and protect
against potential mixture effects are ill-founded. It is high
time such urban myths ceased being cited as gospel.
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